IMMX IMMX
Company Profile ↓Company Overview
IMMX (IMMX) is a publicly traded company listed on with a market capitalization of $505.84M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +275.59% |
| 6 Months: | +50.00% |
| 3 Months: | -0.21% |
| 1 Month: | -20.63% |
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)52.45 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.68M | 6.72M | 7.66M | 10.89M | 10.80M |
| Operating Income | -162.52K | -243.16K | -347.99K | -1.33M | -1.56M | -1.53M | -2.52M | -3.72M | -4.52M | -5.59M | -4.70M | -7.39M | - | -4.68M | -6.72M | -7.66M | -10.89M | -10.80M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.62M | -6.64M | -7.53M | -10.80M | -10.67M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.53M | -6.61M | -7.58M | -10.68M | -10.09M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.82K | 8.91K | 7.72K | 11.27K | 0 |
| Net Income | -1.02M | -208.64K | -403.26K | -1.33M | -1.56M | -1.54M | -2.48M | -3.58M | -4.28M | -5.26M | -4.39M | -7.15M | - | -4.54M | -6.62M | -7.59M | -10.69M | -10.09M |
| Diluted EPS | - | - | - | - | -0.11 | -0.11 | -0.18 | -0.24 | -0.23 | -0.22 | -0.15 | -0.24 | - | -0.15 | -0.22 | -0.24 | - | -0.18 |
| R&D Expense | 24.84K | 62.76K | 29.69K | 629.53K | 607.75K | 695.94K | 1.32M | 2.21M | 2.11M | 3.25M | 2.22M | 4.45M | - | 1.98M | 3.97M | 4.58M | - | 5.98M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -453.85K | -1.35M | -8.22M | -16.14M | -22.67M | -29.96M |
| Net Income | -1.15M | -24.38M | -8.23M | -15.43M | -21.61M | -29.44M |
| Diluted EPS | - | - | -0.59 | -0.89 | -0.76 | -0.89 |
| R&D Expense | 248.15K | 126.53K | 4.20M | 8.74M | 11.29M | 16.26M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 539.60K | - | 14.91M | 19.93M | 22.95M | 104.84M |
| Current Assets | - | - | - | 14.90M | 19.79M | 20.20M | 101.24M |
| Cash & Equivalents | - | 391.09K | - | 13.44M | 17.51M | 17.68M | 93.93M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 255.71K | 1.17M | 1.97M | 0 |
| Total Liabilities | - | 5.27M | - | 1.75M | 3.72M | 9.70M | 11.04M |
| Current Liabilities | - | 5.27M | - | 1.27M | 3.72M | 8.69M | 10.11M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | 50.00K | - | 0 | 1.07M | 1.07M |
| Total Equity | -3.65M | -4.73M | - | 13.16M | 16.41M | 13.25M | 93.80M |
| Shares Outstanding | - | - | - | 13.96M | 19.99M | 27.61M | 53.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -404.69K | -1.59M | -7.41M | -11.37M | -14.60M | -23.93M |
| Investing Cash Flow | - | -802 | - | -52.09K | -1.18M | -7.21M |
| Financing Cash Flow | - | 18.85M | 3.23M | 15.46M | 15.95M | 107.39M |
| Capital Expenditure | - | -802 | - | -52.09K | -1.18M | -732.92K |
| Free Cash Flow | - | -1.59M | - | -11.42M | -15.77M | -24.66M |
| Share Buybacks | - | - | 99.96K | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 24.3% | - | -62.5% | -94.0% | -163.1% | -31.4% |
| ROCE % | 9.6% | - | -60.3% | -99.6% | -159.0% | -31.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMMX
ImmixBio plans one-on-one investor meetings in New York Sept. 14-16 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOam5zUGV6c015OE5yYUlHbjlEV2o4QmpRRGJ0QXJfeDdyNy0weEpubEVmNjlXeDVqaHhaYU5BS0RGVXZGb0ZqS2llZHdZaGIyQnVJRkh2X1hJUDJ6eWpNdHhoMXBxblFXWFdiNWZXaWUwMFNtTXFiczF1QmhESmJoMngySjZobVY2V3lFSk…
Immix Biopharma Announces Participation in Morgan Stanley 24th Annual Global Healthcare Conference and Institutional Investor Meetings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi-wFBVV95cUxQeVVPZUtPTnRfTW5KTGZEM3A3dE1sa1cxODlJWTlDa1B4aHljYXJjWkczdTZyTlBJRWpfSXZFcXpRTGNtQVFtalpVUVpWVVh4TjRmZW1ETHdaS0NIczZZaGZJYjh4NTBPZm5oTWhFcENRbklTMW5Lc1NUOVF2YTdCOTZITzlDejUwbXJLQT…
IMMX INVESTOR ALERT: Holzer & Holzer, LLC Announces Investigation of Immix Biopharma, Inc. - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPSXg2ajF0TEVhb3ZkSElIUVFGcjdtRXRXYmplNllTSXFmRzA3b2hpTHFidENuMk40SzhGNF9jcjlQLTdXMUhCR3FxVFFpZlV3WkVqRThWZU5UaFBadHdlcHg2ZVg2WDUyQjVVdUNmc2JrLWppZVdRZU95Zk4ySG1UTG5mM0MwaXBBVVNjam…
Immix Biopharma stock tumbles amid fugitive CMO report - Investing.com
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNZnRVTHU4V2hwSnI0T0hPRDRQWFRIaXRIbm9FaVBwN1NMRjYxTEQxSHJ6R0cwcXJZb0s1SU5QaHZ5NUFtRlhIdl9GeDNpZjdGVmdkVTV3VVpKa3FTdWdjT0JuV1AzNUFpQkxDTmdPYklQQzJPbURFdVo5WjgtOWl0Ym91Q1pIYUE3a0p6Q0…
IMMX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFB1dlh6SVpUcjBTai1UM2NpOU0tc2g2Zzd3WTJHbGJ4YlRJYmZsQ0Y5YUxqOTVPLXpLb2E2OVZCZjRleHRlcENmc1hwaTNLbmdreGNCNG5WOHp0d25jMkIzdnV2a2xhNXo2NkE1M01JdzhCZ3Jlb0s0Vnhn?oc=5" target="_blank">IMM…
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQTl9oNzJfbGpHVkl3bGdNUTVLM1lqamI3Sy1QcmM1YzN6bWJkN1p1dFZjS2JCcUhlZnA3Z3V5VHlxaFlqdU5vTUE4ekktZVp1YkVrQi13Rjg5M3VyaDdmRWVTRDBkVTRndHNQY0FHdE92dXJHeHp1bnpYbUl1bGVhdExsMGdpeElMSGQ5ck…
IMMX — Frequently Asked Questions
What is the current share price of IMMX?
As of 2026-08-05 17:25 PDT, IMMX trades at $9.54 on NASDAQ/NYSE. Its 52-week range is $1.96 to $12.02.
What is the market capitalisation of IMMX?
IMMX has a market capitalisation of $505.84M on NASDAQ/NYSE.
What is the P/E ratio of IMMX?
IMMX trades at a trailing price-to-earnings (P/E) ratio of -10.72. Its price-to-book (P/B) ratio is 5.39.
What is the return on equity (ROE) of IMMX?
IMMX has a return on equity (ROE) of -31.39%. Its return on capital employed (ROCE) is -31.62%.
Is IMMX a good stock to buy?
This page provides a data-driven analysis of IMMX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.